The main objective of our research group is to develop new tools for patients in Belgium and other parts of the world to rapidly diagnose mycobacterial infections and resistance to antibiotics. After scientific validation, the new tools developed are rapidly used to improve the diagnosis of patients treated at the “Cliniques Universitaires Saint-Luc”.
Our laboratory is part of the pioneers in the use of new generation sequencing (NGS) techniques for the diagnosis of mycobacterial infections. Thanks to our BSL3 laboratory, we can test in vitro new drugs and molecules against tuberculosis as well as to study their mechanism of activity. We are also working on the development of new biomarkers as a potential “point-of-care” test for tuberculosis. Our research priorities are fundamental as well as operational, epidemiological and clinical but also based on the development of computer technologies aimed at interconnecting TB laboratories worldwide. Our group works closely in partnership with Belgian and international academic institutions such as the World Health Organization, and was at the origin of the creation of a start-up company (www.savics.org).